Group 1 - The smart medical sector experienced a significant rally in the afternoon, with notable stocks such as Saili Medical (603716) and Runda Medical (603108) hitting the daily limit up [1] - Other companies in the sector, including Hongbo Pharmaceutical (301230), Mingde Biological (002932), and Kangtai Medical (300869), also saw increases in their stock prices [1] - The market trend suggests a strategy of buying index ETFs to capitalize on the rebound in leading companies within the sector [1]

Core Viewpoint - The AI healthcare sector is experiencing significant growth, highlighted by the surge in stock prices of companies like RunDa Medical, which reached its daily limit, alongside other firms in the industry [1] Industry Summary - A joint announcement from seven departments outlined the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)," aiming for full digital transformation coverage among large-scale pharmaceutical enterprises by 2030 [1] - The plan is expected to accelerate the development of AI in drug manufacturing, indicating a strong governmental push towards integrating AI technologies in the healthcare sector [1] - According to Xinda Securities, 2025 is projected to be a pivotal year for rapid advancements in AI healthcare [1]

Summary of the Conference Call for RunDa Medical Industry and Company Overview - The conference call discusses the medical testing industry, specifically focusing on RunDa Medical, which is affected by policies such as medical anti-corruption and centralized procurement price reductions [2][3][4]. Key Points and Arguments Financial Performance - In Q1 2025, RunDa Medical reported a net loss of 69.26 million yuan, a year-on-year decline of 19.8% [2][5]. - The company's revenue for 2024 was 8.012 billion yuan, a decrease of approximately 9% compared to the previous year, with a net profit of 55.28 million yuan, down about 80% [3]. - The centralized testing center generated revenue of 2.445 billion yuan, maintaining a stable customer base of 432 clients, an increase of 23 clients year-on-year [3][4]. AI Business Development - RunDa Medical launched the 2.0 version of its AI product, CDX Liangyi Xiaohui, and partnered with Huawei to introduce the Huasheng integrated machine, providing digital solutions to 105 top-tier hospitals [2][4]. - The AI business is experiencing rapid growth, with Q1 revenue approaching the total revenue of the previous year, indicating strong market recognition [5]. - The company is focusing on enhancing its AI product iterations and expanding market education and commercialization efforts [18][24]. Market Challenges and Strategies - The medical testing market is facing a slowdown in demand due to policy changes, leading to increased service costs and fixed asset depreciation [2][3]. - RunDa Medical is optimizing its business structure and internal management to improve operational quality despite the challenges [3][4]. - The company anticipates that cash flow will remain stable throughout the year, despite profit pressures from centralized procurement impacts [11]. Future Outlook - The company plans to continue expanding its AI business, targeting the addition of 50 to 100 regional testing center clients annually [19][21]. - RunDa Medical is also exploring C-end business opportunities, including partnerships with insurance companies and health management platforms [13][15][24]. - The long-term goal is to establish a comprehensive product matrix in the AI medical field, balancing B-end and C-end product development [24][25]. Additional Important Information - The company has received awards for its innovative AI service model, which combines data and capabilities to drive healthcare digital transformation [2][4]. - RunDa Medical's AI business is expected to face initial losses due to high R&D and expansion costs, but it has a projected gross margin of 60% to 70% in the long run [22][23]. - The impact of new tax policies and international trade tensions on the IVD industry is considered limited, with more significant effects stemming from domestic procurement policies [5][6]. This summary encapsulates the critical insights from the conference call, highlighting the financial performance, AI business development, market challenges, and future strategies of RunDa Medical.

Fundraising and Usage Overview - As of December 31, 2024, the company raised a total of RMB 540,100,000 through convertible bonds, with a net amount of RMB 537,907,547 after deducting issuance costs [1] - The actual investment amount for the "Comprehensive Service Expansion Project" is RMB 66,085.43 million, while the actual raised funds available for investment are RMB 53,790.75 million, indicating a shortfall that the company plans to cover through self-financing [2] Pre-Investment and Replacement - Prior to the arrival of the raised funds, the company invested RMB 93,618,000 from its own resources into the project to ensure smooth implementation [4] - The board approved the use of raised funds to replace the pre-invested self-financing amount of RMB 93,618,000 [4] Temporary Use of Idle Funds - As of December 31, 2024, the company temporarily used RMB 18,000,000 of idle raised funds to supplement working capital, with a maximum limit of RMB 25,000,000 approved by the board [5][6] - The company has consistently returned the used funds to the designated account within the stipulated timeframes [5][6][6] Project Delays - The "Comprehensive Service Expansion Project" has been postponed multiple times, with the latest extension approved to May 30, 2026, due to actual operational needs [9][10] Financial Performance - For the year 2024, the company generated sales revenue of RMB 34,547,960 and a net profit of RMB 207,030 from the raised funds, resulting in a sales profit margin of 0.60% [16] - The project is expected to achieve an average annual sales revenue of RMB 90,611,780 and an average annual net profit of RMB 7,781,910 upon reaching full capacity [16] Profit Distribution Plan - The company plans to distribute a cash dividend of RMB 0.30 per share, totaling RMB 18,109,208.37, based on a total share capital of 603,640,279 shares as of December 31, 2024 [20] - The cash dividend payout ratio for the year is 32.76% [20] Guarantee and Risk Management - The company plans to provide guarantees for a total of RMB 422,100,000 in credit limits for its subsidiaries in 2025, with an actual guarantee balance of RMB 314,777,510 as of the announcement date [28] - The company has ensured that the guarantees are backed by equal guarantees from other shareholders of the subsidiaries [28]

Core Viewpoint - The company, Shanghai RunDa Medical Technology Co., Ltd., is a leading comprehensive service provider in the IVD (in vitro diagnostics) industry, focusing on integrating data, services, and solutions to enhance laboratory efficiency and management [11][15][24]. Financial Performance - For the reporting period, the company achieved operating revenue of 831,178.04 million yuan, a year-on-year decrease of 9.13%. The net profit attributable to shareholders was 5,528.06 million yuan, down 79.77% year-on-year [26]. Industry Overview - The IVD circulation service industry is experiencing stable growth, with the market size for intermediary channel testing service providers estimated at approximately 1,500-1,800 billion yuan. The growth is driven by an aging population and increasing healthcare demands [12][13]. - The domestic public hospital testing revenue reached 452 billion yuan in 2022, reflecting a year-on-year growth of 10.4% [12]. Market Dynamics - The industry is undergoing a transformation towards concentration and specialization, with policies such as the two-invoice system and centralized procurement reshaping the competitive landscape. The market concentration (CR10) increased from 15% in 2021 to 28% in 2023 [13]. - There is a growing demand for cost reduction and efficiency improvement in medical institutions, driving the need for innovative service models [13][14]. Business Model - The company operates a dual business model consisting of a comprehensive service platform and an industrial segment. The service platform includes traditional supply chain services, centralized services, and third-party laboratory testing [15][20]. - The industrial segment focuses on IVD product research and development, emphasizing innovation and diversification in product offerings [20][21]. Strategic Initiatives - The company is leveraging AI and big data to enhance laboratory management and clinical decision-making, aiming to create a comprehensive digital solution for healthcare [21][24]. - The establishment of regional testing centers is a key initiative to improve resource sharing and operational efficiency in the healthcare system [14][18]. Future Outlook - The company is well-positioned to benefit from the ongoing healthcare reforms and the increasing demand for integrated diagnostic services, which are expected to drive future growth [12][24].

上海润达医疗科技股份有限公司 董事会 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，上海润达医疗 科技股份有限公司（以下简称"公司"）董事会，就公司在任独立董事王晶晶、何 嘉、CHAN HWANG TONG、冯国富的独立性情况进行评估并出具如下专项意见： 2025 年 4 月 25 日 经核查独立董事王晶晶、何嘉、CHAN HWANG TONG、冯国富的任职经历 以及签署的独立性自查报告，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情 况。因此，公司独立董事符合《上市公司独立董事管理办法》《上海证券交易所 股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等法律法规中关于独立董事任职资格及独立性的相关要求。 董事会关于独立董事独立性情况的专项报告 上海润达医疗科技股份有限公司 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-014 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于公司 2025 年度担保预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 被担保人名称： 十四家全资子公司：杭州润达、惠中医疗、惠中生物、哈尔滨润达、鑫 海润邦、青岛益信、青岛润达、惠中诊断、上海润林、广东润达、润达 供应链杭州、山东润达康源、杭州铭和元、中鼎达科； 十五家控股子公司：云南康泰、武汉尚检、惠中榕嘉、黑龙江龙卫、济 南润达、合肥三立、杭州怡丹、润达榕嘉、上海润医、苏州润达、武汉 优科联盛、合肥润达、润澜生物、重庆润达、安徽泽芬。 本次担保金额及已实际为其提供的担保余额：公司 2025 年度为公司全 资及控股子公司申请总额不超过人民币 422,100 万元的授信额度提供连 带责任保证担保，截至公告日实际为其提供的担保余额总计人民币 314,777.51 万元。 本次担 ...

上海润达医疗科技股份有限公司（以下简称"公司"）聘请众华会计师事务 所（特殊普通合伙）（以下简称"众华"）作为公司 2024 年度财务审计机构和内 控审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会 计师事务所管理办法》，公司对众华 2024 年度审计过程中的履职情况进行评估。 具体情况如下： 一、 2024 年年审会计师事务所基本情况 （一）资质条件 众华于 2013 年 12 月 2 日成立，注册地址为上海市嘉定工业区叶城路 1630 号 5 幢 1088 室，首席合伙人为陆士敏。截至 2024 年末，众华合伙人数量为 68 人、注册会计师人数 359 人（其中签署过证券服务业务审计报告的注册会计师人 数超过 180 人）。2024 年度上市公司审计客户家数为 73 家，行业包括：制造业， 房地产业、信息传输、软件和信息技术服务业等。 （二）聘任会计师事务所履行的程序 公司于 2024 年 12 月 4 日、2024 年 12 月 20 日分别召开了第五届董事会第 十九次会议和 2024 年第三次临时股东大会，审议通过《关于变更会计师事务所 的议案》，同意聘任众华为本公司 2024 年 ...

上海润达医疗科技股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监督职责情况的报告 上海润达医疗科技股份有限公司（以下简称"公司"）聘请众华会计师事务所（特 殊普通合伙）（以下简称"众华"）作为公司 2024 年度财务审计机构和内控审计机构。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《国有 企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《公司章程》的相关规定的要求，董事会审计委员会本着勤勉尽 责的原则，恪尽职守，认真履职。董事会审计委员会对会计师事务所 2024 年度的审计 工作情况履行了监督职责。具体情况如下： 一、 2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 众华于 2013 年 12 月 2 日成立，注册地址为上海市嘉定工业区叶城路 1630 号 5 幢 1088 室，首席合伙人为陆士敏。截至 2024 年末，众华合伙人数量为 68 人、注册会计 师人数 359 人（其中签署过证券服务业务审计报告的注册会计师人数超过 180 人）。2024 年度上市公司审计客户家数为 73 家， ...

上海润达医疗科技股份有限公司 2025年度"提质增效重回报"行动方案 为深入贯彻党的二十大和中央金融工作会议精神，认真落实《国务院关于加 强监管防范风险推动资本市场高质量发展的若干意见》，上海润达医疗科技股份 有限公司（以下简称"公司"）积极响应上海证券交易所《关于开展沪市公司"提 质增效重回报"专项行动的倡议》，深入践行以"投资者为本"的理念，推动公 司高质量发展，不断提升核心竞争力和企业价值，增强投资者回报，保护投资者 尤其是中小投资者合法权益，特制订公司 2025年度"提质增效重回报"行动方案， 具体如下： 一、夯实核心业务，数字化赋能传统业务提升经营质量 公司作为国内医学实验室综合服务商，在体外诊断行业深耕二十余年，致力 于为各类实验室提供体外诊断产品、技术服务支持、实验室运营管理等全方位的 综合服务。在多年的经营中始终坚持以服务客户为宗旨的发展策略，秉承为客户 创造价值的服务理念，通过构建完善的综合服务体系，全方位地契合了医学实验 室的应用及发展需求，为客户创造价值，帮助客户实现精细化管理，降低综合运 营成本，提升医疗效率和诊断服务水平，达到降本增效的目的，形成较为突出的 竞争优势。 近年来，面对复 ...